Liposomes are spherical lipid bilayers from 50 nm to 1000 nm in diameter that serve as convenient delivery vehicles for biologically active compounds. The field of liposome research has expanded considerably over the last 30 years. It is now possible to engineer a wide range of liposomes varying in size, phospholipid composition and surface characteristics to suit the specific application for which they are intended. This paper gives an overview of the main advances in liposome research from a point of view of their applications in medicine. Aqueous contrast enhancing agents entrapped in liposomal carriers can be targeted to the liver and spleen and distinctions can be made between normal and tumorous tissue using computed tomography. Topical application of liposomes has great potential in dermatology. Liposomes have been used to deliver anticancer agents in order to reduce the toxic effects of the drugs when given alone or to increase the circulation time and effectiveness of the drugs. From the original concept of encapsulating hemoglobin in an inert shell, liposome-encapsulated hemoglobin (LEH) has evolved into a fluid proven to carry oxygen, capable of surviving for reasonable periods in the circulation and amenable to large-scale production. Liposomes may be used to target specific cells by attaching amino acid fragments such as antibodies or proteins or appropriate fragments that target specific receptor sites. Liposomal DNA delivery vectors and further enhancements in the forms of LPDI and LPDII are some of the safest and potentially most versatile transfer vectors used to date. DNA vaccination and improved efficiency of gene therapy are just a few of the upcoming applications of liposomes.
Get full access to this article
View all access options for this article.
References
1.
1. Langner, M., Kral, T. E.1999. “Liposome-Based Drug Delivery Systems”, Pol J. Pharmacol51: 211–222.
2.
2. Bangham, A. D., Standish, M. M., Watkins, J. C., Weissmann, G.1967. “The Diffusion of Ions from a Phospholipid Model Membrane System”, Protoplasma, 63: 183–187.
4. Bangham, A. D.1972. “Lipid Bilayers and Biomembranes”, Annu Rev Biochem, 41: 753–776.
5.
5. Bangham, A. D.1993. “Liposomes: the Babraham Connection”, Chem Phys Lipids, 64: 275–285.
6.
6. Bangham, A. D.1992. “Liposomes: Realizing Their Promise”, Hosp Pract (Off Ed), 15: 51–56.
7.
7. Mori, A., Klibanov, A. L., Torchilin, V. P., Huang, L.1991. “Influence of the Steric Barrier Activity of Amphipathic Poly(ethyleneglycol) and Ganglioside GM1 on the Circulation Time of Liposomes and on the Target Binding of Immunoliposomes in vivo”, FEBS Lett, 284: 263–266.
8.
8. Allen, T. M.1994. “The Use of Glycolipids and Hydrophilic Polymers in Avoiding Rapid Uptake of Liposomes by the Mononuclear Phagocytic System”, Advanced Drug Deliv. Rev., 13: 285–309.
9.
9. Needham, D., McIntosh, T. J., Lasic, D. D.1992. “Repulsive Interactions and Mechanical Stability of Polymer-Grafted Lipid Membranes”, Biochim Biophys Acta, 1108: 40–48.
10.
10. Farhood, H., Serbina, N., Huang, L.1995. “The Role of Dioleoyl Phosphatidylethanolamine in Cationic Liposome Mediated Gene Transfer”, Biochim Biophys Acta, 1235: 289–295.
11.
11. Debs, R. J., Health, T. D., Papahadjopoulos, D.1987. “Targeting of Anti-Thy 1.1 Monoclonal Antibody Conjugated Liposomes in Thy1.1 Mice After Intravenous Administration”, Biochim Biophys Acta, 901: 183–190.
12.
12. Allen, T. M., Ahmad, I., Lopes de Menezes, D. E., Moase, E. H.1995. “Immunoliposome-Mediated Targeting of Anti-Cancer Drugs In Vivo”, Biochem Soc Trans, 23: 1073–1079.
13.
13. Papahadjopoulos, D., Gabizon, A.1987. “Targeting of Liposomes to Tumor Cells In Vivo”, Ann NY Acad Sci., 507: 64–74.
14.
14. Maruyama, K., Kennel, S. J., Huang, L.1990. “Lipid Composition is Important for Highly Efficient Target Binding and Retention of Immunoliposomes”, Proc Natl Acad Sci USA, 87: 5744–5748.
15.
15. Ahmad, I., Longenecker, M., Samuel, J., Allen, T. M.1993. “Antibody-Targeted Delivery of Doxorubicin Entrapped in Sterically Stabilized Liposomes Can Eradicate Lung Cancer in Mice”, Cancer Res, 53: 1484–1488.
16.
16. Juliano, R. L. and Stamp, D.1975. “The Effect of Particle Size and Charge on Clearance Rates of Liposomes and Liposome Encapsulated Drugs”, Biochem. Biophys. Res. Commun., 63: 651–658.
17.
17. Mauk, M. R., Gamble, R. C.1979. “Stability of Lipid Vesicles in Tissues of the Mouse: A Gamma-Ray Perturbed Angular Correlation Study”, Proc Natl Acad Sci USA, 76: 765–769.
18.
18. Allen, T. M., Hansen, C.1991. “Pharmacokinetics of Stealth Versus Conventional Liposomes: Effect of Dose”, Biochim Biophys Acta, 1068: 133–141.
19.
19. Allen, T. M., Hansen, C. B., Guo, L. S.1993. “Subcutaneous Administration of Liposomes: A Comparison with the Intravenous and Intraperitoneal Routes of Injection”, Biochim Biophys Acta, 1150: 9–16.
20.
20. Nishikawa, K., Arai, H., Inoue, K.1990. “Scavenger Receptor-Mediated Uptake and Metabolism of Lipid Vesicles Containing Acidic Phospholipids by Mouse Peritoneal Macrophages”, J. Biol Chem, 265: 5226–5231.
21.
21. Senior, J. H., Trimble, K. R., Maskiewicz, R.1991. “Interaction of Positively-Charged Liposomes with Blood: Implications for Their Application In Vivo”, Biochim Biophys Acta, 1070: 173–179.
22.
22. Gregoriadis, G., Davis, C.1979. “Stability of Liposomes In Vivo and In Vitro is Promoted by Their Cholesterol Content and the Presence of Blood Cells”, Biochem Biophys Res Commun., 89: 1287–1293.
23.
23. Weissmann, G., Cohen, C., Hoffstein, S.1977. “Introduction of Enzymes, by Means of Liposomes, Into Non-Phagocytic Human Cells in vitro”, Biochim Biophys Acta, 498: 375–385.
24.
24. Allen, T. M., Hansen, C., Martin, F., Redemann, C., Yau-Young, A.1991. “Liposomes Containing Synthetic Lipid Derivatives of Poly(ethyleneglycol) Show Prolonged Circulation Half-Lives in vivo”, Biochim Biophys Acta, 1066: 29–36.
25.
25. Woodle, M. C., Matthay, K. K., Newman, M. S., Hidayat, J. E., Collins, L. R., Redemann, C., Martin, F. J., Papahadjopoulos, D.1992. “Versatility in Lipid Compositions Showing Prolonged Circulation with Sterically Stabilized Liposomes”, Biochim Biophys Acta, 1105: 193–200.
26.
26. Klibanov, A. L., Khaw, B. A., Nossiff, N., O’Donnell, S. M.Huang, L., Slinkin, M. A., Torchilin, V. P.1991. “Targeting of Macromolecular Carriers and Liposomes by Antibodies to Myosin Heavy Chain”, Am J Physiol, 261: 60–65.
27.
27. Wu, N. Z., Da, D., Rudoll, T. L., Needham, D., Whorton, A. R., Dewhirst, M. W.1993. “Increased Microvascular Permeability Contributes to Preferential Accumulation of Stealth Liposomes in Tumor Tissue”, Cancer Res, 53: 3765–3670.
28.
28. Northfelt, D. W., Martin, F. J., Working, P., Volberding, P. A., Russell, J., Newman, M., Amantea, M. A., Kaplan, L. D.1996. “Doxorubicin Encapsulated in Liposomes Containing Surface-Bound Polyethylene Glycol: Pharmacokinetics, Tumor Localization, and Safety in Patients with AIDS-Related Kaposi’s Sarcoma”, J Clin Pharmacol, 36: 55–63.
29.
29. Allen, T. M., Brandeis, E., Hansen, C. B., Kao, G. Y., Zalipsky, S.1995. “A New Strategy for Attachment of Antibodies to Sterically Stabilized Liposomes Resulting in Efficient Targeting to Cancer Cells”, Biochim Biophys Acta, 1237: 99–108.
30.
30. Hwang, K. J., Luk, K. F., Beaumier, P. L.1980. “Hepatic Uptake and Degradation of Unilamellar Sphingomyelin/Cholesterol Liposomes: A Kinetic Study”, Proc Natl Acad Sci USA, 77: 4030–4034.
31.
31. Huang, C.1969. “Studies on Phosphatidylcholine Vesicles. Formation and Physical Characteristics”, Biochemistry8: 344–352.
32.
32. Hope, M. J., Kitson, C. N.1993. “Liposomes. A Perspective for Dermatologists”, Dermatol Clin, 11: 143–154.
33.
33. Jonah, M. M., Cerny, E. A., Rahman, Y. E.1975. “Tissue Distribution of EDTA Encapsulated Within Liposomes of Varying Surface Properties”, Biochim Biophys Acta, 401: 336–348.
34.
34. Kimelberg, H. K.1976. “Differential Distribution of Liposome-Entrapped [3H]methotrexate and Labelled Lipids After Intravenous Injection in a Primate”, Biochim Biophys Acta, 448: 531–550.
35.
35. Bangham, A. D.1968. “Membrane Models with Phospholipids”, Prog Biophys Mol Biol, 18: 29–95.
36.
36. Papahadjopoulos, D., Miller, N.1967. “Phospholipid Model Membranes. I. Structural Characteristics of Hydrated Liquid Crystals”, Biochim Biophys Acta, 135: 624–638.
37.
37. Gershon, H., Ghirlando, R., Guttmann, S. B., Minsky, A.1993. “Mode of Formation and Structural Features of DNA-Cationic Liposome Complexes Used for Transfection”, Biochemistry, 32: 7143–7151.
38.
38. Sternberg, B., Sorgi, F. L., Huang, L.1994. “New Structures In Complex Formation Between DNA and Cationic Liposomes Visualized by Freeze-Fracture Electron Microscopy”, FEBS Lett, 356: 361–366.
39.
39. Gustafsson, J., Arvidson, G., Karlsson, G., Almgren, M.1995. “Complexes Between Cationic Liposomes and DNA Visualized by Cryo-TEM”, Biochim Biophys Acta, 1235: 305–312.
41. Xu, Y., Szoka, F. C. Jr.1996. “Mechanism of DNA Release From Cationic Liposome/DNA Complexes Used in Cell Transfection”, Biochemistry, 35: 5616–5623.
42.
42. Humphries, G. M.1981. “Evidence for Direct Control of an In Vitro Plaque-Forming Cell Response by Quantitative Properties of Intact, Fluid, Haptenated Liposomes: A Potential Model System for Antigen Presentation by Macrophages”, J. Immunol, 126: 688–692.
43.
43. Petty, H. R., McConnell, H. M.1983. “Cytochemical Study of Liposome and Lipid Vesicle Phagocytosis”, Biochim Biophys Acta, 735: 77–85.
44.
44. Papahadjopoulos, D., Vail, W. J., Jacobson, K., Poste, G.1975. “Cochleate Lipid Cylinders: Formation by Fusion of Unilamellar Lipid Vesicles”, Biochim Biophys Acta, 394: 483–491.
45.
45. Kimelberg, H. K.1976. “Protein-Liposome Interactions and Their Relevance to the Structure and Function of Cell Membranes”, Mol Cell Biochem, 10: 171–190.
46.
46. Perkins, W. R., Minchey, S. R., Ahl, P. L., Janoff, A. S.1993. “The Determination of Liposome Captured Volume”, Chem Phys Lipids, 64: 197–217.
47.
47. Li, X., Hirsh, D. J., Cabral-Lilly, D., Zirkel, A., Gruner, S. M., Janoff, A. S., Perkins, W. R.1998. “Doxorubicin Physical State in Solution and Inside Liposomes Loaded Via a pH Gradient”, Biochim Biophys Acta, 1415: 23–40.
48.
48. Bano, M. C., Braco, L., Abad, C.1988. “New High-Performance Liquid Chromatography-Based Methodology for Monitoring the Conformational Transitions of Self-Associating Hydrophobic Peptides, Incorporated Into Liposomes”, Chromatogr, 458: 105–116.
49.
49. McDougall, I. R., Dunnick, J. K., McNamee, M. G., Kriss, J. P.1974. “Distribution and Fate of Synthetic Lipid Vesicles in the Mouse: A Combined Radionuclide and Spin Label Study”, Proc. Natl Acad Sci USA, 71: 3487–3491.
50.
50. Seltzer, S. E.1988. “Contrast-Carrying Liposomes. Current Status”, Invest Radiol, 23: S122–S125.
51.
51. Seltzer, S. E., Swensson, R. G., Judy, P. F., Nawfel, R. D.1988. “Size Discrimination in Computed Tomographic Images. Effects of Feature Contrast and Display Window”, Invest Radiol, 23: 455–462.
52.
52. White, C., Slifkin, M., Seltzer, S. E., Blau, M., Adzamli, I. K., Adams, D. F.“Biodistribution and Clearance of Contrast-Carrying MREV Liposomes”, Invest Radiol, 25: 1125–1129.
53.
53. Seltzer, S. E., Blau, M., Herman, L. W., Hooshmand, R. L., Herman, L. A., Adams, D. F., Minchey, S. R., Janoff, A. S.1995. “Contrast Material-Carrying Liposomes: Biodistribution, Clearance, and Imaging Characteristics”, Radiology, 194: 775–781.
54.
54. Adzamli, I. K., Seltzer, S. E., Slifkin, M., Blau, M., Adams, D. F.1990. “Production and Characterization of Improved Liposomes Containing Radiographic Contrast Media”, Invest Radiol, 25: 1217–1223.
55.
55. Simon, R. H., Ho, S. Y., D’Arrigo, J., Wakefield, A., Hamilton, S. G.1990. “Lipid-Coated Ultrastable Microbubbles as a Contrast Agent in Neurosonography”, Invest Radiol, 25: 1300–1304.
56.
56. Lasch, J., Wohlrab, W.1986. “Liposome-Bound Cortisol: A New Approach to Cutaneous Therapy”, Biomed Biochim Acta, 45: 1295–1299.
57.
57. Masini, V., Bonte, F., Meybeck, A., Wepierre, J.1993. “Cutaneous Bioavailability in Hairless Rats of Tretinoin in Liposomes or Gel”, J. Pharm Sci, 82: 17–21.
58.
58. Wolf, P., Cox, P., Yarosh, D. B., Kripke, M. L.1995. “Sunscreens and T4N5 Liposomes Differ in Their Ability to Protect Against Ultraviolet-Induced Sunburn Cell Formation, Alterations of Dendritic Epidermal Cells, and Local Suppression of Contact Hypersensitivity”, J Invest Dermatol, 104: 287–292.
59.
59. Vonka, V., Petrovska, P., Borecky, L., Roth, Z.1995. “Increased Effects of Topically Applied Interferon on Herpes Simplex Virus-Induced Lesions by Caffeine”, Acta Virol, 39: 125–130.
60.
60. Syed, T. A., Khayyami, M., Kriz, D., Svanberg, K., Kahlon, R. C., Admad, S. A.1995. “Management of Genital Warts in Women with Human Leukocyte Interferon-Alpha vs. Podophyllotoxin in Cream: A Placebo-Controlled, Double-Blind, Comparative Study”, Mol Med, 73: 255–258.
61.
61. Takeuchi, M., Tredget, E. E., Scott, P. G., Kilani, R. T., Ghahary, A.1999. “The Antifibrogenic Effects of Liposome-Encapsulated IFN-Alpha2b Cream on Skin Wounds”, J. Interferon Cytokine Res, 19: 1413–1419.
62.
62. Cevc, G., Blume, G.1992. “Lipid Vesicles Penetrate Into Intact Skin Owing to the Transdermal Osmotic Gradients and Hydration Force”, Biochim Biophys Acta, 1104: 226–232.
63.
63. Hoffman, R. M.1998. “Topical Liposome Targeting of Dyes, Melanins, Genes, and Proteins Selectively to Hair Follicles”, J Drug Target, 5: 67–74.
64.
64. Li, L., Hoffman, R. M.1995. “Model of Selective Gene Therapy of Hair Growth: Liposome Targeting of the Active Lac-Z Gene to Hair Follicles of Histocultured Skin”, In Vitro Cell Dev Biol Anim, 31: 11–13.
65.
65. Torres, P. F., Slegers, T. P., Peek, R., van Rooijen, N., van der Gaag, R., Kijlstra, A., de Vos, A. F.1999. “Changes in Cytokine mRNA Levels in Experimental Corneal Allografts After Local Clodronate-Liposome Treatment”, Invest Ophthalmol Vis Sci, 40: 3194–3201.
66.
66. Uziely, B., Jeffers, S., Isacson, R., Kutsch, K., Wei-Tsao, D., Yehoshua, Z., Libson, E., Muggia, F. M., Gabizon, A.1995. “Liposomal Doxorubicin: Antitumor Activity and Unique Toxicities During Two Complementary Phase I Studies”, J Clin Oncol, 13: 1777–1785.
67.
67. Northfelt, D. W., Dezube, B. J., Thommes, J. A., Levine, R., Von Roenn, J. H., Dosik, G. M., Rios, A., Krown, S. E., DuMond, C., Mamelok, R. D.1997. “Efficacy of Pegylated-Liposomal Doxorubicin in the Treatment of AIDS-Related Kaposi’s Sarcoma After Failure of Standard Chemotherapy”, J Clin Oncol, 15: 653–659.
68.
68. Ranson, M. R., Carmichael, J., O’Byrne, K., Stewart, S., Smith, D., Howell, A.1997. “Treatment of Advanced Breast Cancer with Sterically Stabilized Liposomal Doxorubicin: Results of a Multicenter Phase II Trial”, J Clin Oncol, 15: 3185–3191.
69.
69. Muggia, F. M., Hainsworth, J. D., Jeffers, S., Miller, P., Groshen, S., Tan, M., Roman, L., Uziely, B., Muderspach, L., Garcia, A., Burnett, A., Greco, F. A., Morrow, C. P., Paradiso, L. J., Liang, L. J.1997. “Phase II Study of Liposomal Doxorubicin in Refractory Ovarian Cancer: Antitumor Activity and Toxicity Modification by Liposomal Encapsulation”, J Clin Oncol, 15: 987–993.
70.
70. Alving, C. R., Schneider, I., Swartz, G. M. Jr., Steck, E. A.1979. “Sporozoite-Induced Malaria: Therapeutic Effects of Glycolipids in Liposomes”, Science, 205: 1142–1144.
71.
71. Petersen, E. A., Grayson, J. B., Hersh, E. M., Dorr, R. T., Chiang, S. M., Oka, M., Proffitt, R. T.1996. “Liposomal Amikacin: Improved Treatment of Mycobacterium Avium Complex Infection in the Beige Mouse Model”, J Antimicrob Chemother, 38: 819–828.
72.
72. Leff, J. A., Baer, J. W., Kirkman, J. M., Bodman, M. E., Shanley, P. F., Cho, O. J., Ostro, M. J., Repine, J. E.1994. “Liposome-Entrapped PGE1 Posttreatment Decreases IL-1 Alpha-Induced Neutrophil Accumulation and Lung Leak in Rats”, J. Appl Physiol, 76: 151–157.
73.
73. Suntres, Z. E., Shek, P. N.1995. “Liposomal Alpha-Tocopherol Alleviates the Progression of Paraquat-Induced Lung Damage”, J Drug Target, 2: 493–500.
74.
74. Shaw, I. H., Knight, C. G., Thomas, D. P., Phillips, N. C., Dingle, J. T.1979. “Liposome-Incorporated Corticosteroids: I. The Interaction of Liposomal Cortisol Palmitate with Inflammatory Synovial Membrane”, Br J Exp Pathol, 60: 142–150.
75.
75. Shinozawa, S., Araki, Y., Oda, T.1979. “Distribution of [3H]Prednisolone Entrapped in Lipid Layer of Liposome After Intramuscular Administration in Rats”, Res. Commun Chem Pathol Pharmacol, 24: 223–232.
76.
76. Konigsberg, P. J., Debrick, J. E., Pawlowski, T. J., Staerz, U. D.1999. “Liposome Encapsulated Aurothiomalate Reduces Collagen-Induced Arthritis in DBA/1J Mice”, Biochim Biophys Acta, 1421: 149–162.
77.
77. Rabinovici, R., Rudolph, A. S., Ligler, F. S., Yue, T. L., Feuerstein, G.1990. “Liposome-Encapsulated Hemoglobin: An Oxygen-Carrying Fluid”, Circ Shock, 32: 1–17.
78.
78. Szebeni, J., Alving, C. R.1999. “Complement-Mediated Acute Effects of Liposome-Encapsulated Hemoglobin”, Artif Cells Blood Substit Immobil Biotechnol, 27: 23–41.
79.
79. Kirpotin, D., Park, J. W., Hong, K., Zalipsky, S., Li, W. L., Carter, P., Benz, C. C.Papahadjopoulos, D.1997. “Sterically Stabilized Anti-HER2 Immunoliposomes: Design and Targeting to Human Breast Cancer Cells in vitro”, Biochemistry, 36: 66–75.
80.
80. Lasic, D. D.1998. “Novel Applications of Liposomes”, Trends Biotechnol, 16: 307–321.
81.
81. Amantea, M., Newman, M. S., Sullivan, T. M., Forrest, A., Working, P. K.1999. “Relationship of Dose Intensity to the Induction of Palmar-Plantar Erythrodysesthia by Pegylated Liposomal Doxorubicin in Dogs”, Hum Exp Toxicol, 18: 17–26.
